Roche's Enicepatide: A Game-Changer in the Obesity Drug Race

Roche's experimental obesity drug, Enicepatide, showed promising results in a mid-stage trial, with patients losing an average of 22.7% of their body weight. The dual-acting drug competes with treatments from Novo Nordisk and Eli Lilly, and analysts expect the obesity drug market to reach $100 billion annually within the next decade.

Roche, the Swiss pharmaceutical giant, announced on Friday that its experimental obesity drug, Enicepatide, has achieved significant weight loss results in a mid-stage trial. Patients lost an average of 22.7% of their body weight, with over 26% achieving a weight reduction of at least 30% when administered the highest dose.

Enicepatide competes with Novo Nordisk's Wegovy and Eli Lilly's Zepbound in a rapidly advancing obesity drug market, which analysts predict could generate over $100 billion annually in the coming decade. The weight loss achieved with Enicepatide was recorded after just 48 weeks, outperforming Wegovy's 68-week results and closely rivaling Zepbound's achievements.

The drug mimics hormones GLP-1 and GIP to facilitate weight loss. Roche's head of cardiovascular, renal, and metabolism product development, Manu Chakravarthy, noted the continued potential for weight loss past the study period. The drug showed manageable side effects, with only 5.9% of patients discontinuing treatment due to adverse events.